Drugs / GLPG2737
GLPG2737
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03540524 | May 2018 → Mar 2019 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03450720 | Jun → Aug 2017 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03128606 | Mar 2017 → Feb 2018 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03410979 | Nov 2016 → Aug 2017 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04578548 | Nov 2020 → Dec 2022 | autosomal dominant polycystic kidney disease | Lakefront Biotherapeutics NV | Terminated | Missed primary |
| Phase 2 | NCT03474042 | Nov 2017 → Apr 2018 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-06-28 | Lakefront Biotherapeutics NV | Results Topline results of PELICAN trial and update on triple combo development plans lakefrontbio.com ↗
GLPG2737 achieved primary efficacy endpoint and was well-tolerated in patients |
| 2017-06-20 | Lakefront Biotherapeutics NV | Results Galapagos’ R&D Update 2017: rapidly advancing our product candidates lakefrontbio.com ↗
Galapagos reports that Phase 1 results on GLPG2451, GLPG2222 and GLPG2737 showed favorable findings relating to safety and tolerability of the individual components that constitute our current most advanced potential triple combination therapy. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-06-28 | Lakefront Biotherapeutics NV | Topline results of PELICAN trial and update on triple combo development plans lakefrontbio.com ↗ |
| 2017-06-20 | Lakefront Biotherapeutics NV | Galapagos’ R&D Update 2017: rapidly advancing our product candidates lakefrontbio.com ↗ |
| 2016-11-28 | Lakefront Biotherapeutics NV | Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737 lakefrontbio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG2737 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04578548 ↗ |
| Known as | ABBV 2737 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068548 ↗ |
| Known as | G-1117337 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068548 ↗ |
| Modality | Small molecule | — CHEMBL6068548 ↗ |
| Route | Oral | “GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days” NCT03128606 ↗ |